CRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to manufacture and sell generic versions of two related diabetes treatments. CRA provided a report analyzing evidence of commercial success for the branded pharmaceutical products as well as deposition and trial testimony.
Patent damages jury verdicts aren't always end of the story
It has been over three years since Intel Corporation was ordered by a federal jury to pay VLSI Technology LLC over $2 billion in damages. During that time, the...